Mechanisms of Action for Treatments in Multiple Sclerosis (original) (raw)

• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–17
  Article PubMed CAS Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–11
  Article PubMed CAS Google Scholar
• Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169–78
  Article PubMed CAS Google Scholar
• Neuhaus O, Archelos JJ, Hartung H-P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003; 24(3): 131–8
  Article PubMed CAS Google Scholar
• PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. University of British Columbia MS/MRI Analysis Group. Neurology 2001; 56(12): 1628–36
  Article Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49(3): 290–7
  Article PubMed CAS Google Scholar
• Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–25
  Article PubMed Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348(1): 15–23
  Article PubMed CAS Google Scholar
• Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354(9191): 1691–5
  Article PubMed CAS Google Scholar
• Rice GPA, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145–55
  Article PubMed CAS Google Scholar
• Gonsette RE. New immunosuppressants with potential implication in multiple sclerosis. J Neurol Sci 2004; 223: 87–93
  Article PubMed CAS Google Scholar
• Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35–9
  Article PubMed CAS Google Scholar
• Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909–13
  Article PubMed CAS Google Scholar
• Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 2004; 101(30): 11058–63
  Article PubMed CAS Google Scholar
• Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004; 63(12 Suppl. 6): S15–18
  Article PubMed CAS Google Scholar
• Chan A, Weilbach FX, Toyka KV, et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152–8
  Article PubMed CAS Google Scholar
• Ota K, Matsui M, Milford EL, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183–7
  Article PubMed CAS Google Scholar
• Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40: 1770–6
  Article PubMed CAS Google Scholar
• Hartung H-P, Bar-Or A. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251Suppl. 5: V12–29
  Article PubMed Google Scholar
• Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682–9
  Article PubMed CAS Google Scholar
• Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 2004; 33(2): 109–42
  Article PubMed CAS Google Scholar
• Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–8
  Article PubMed CAS Google Scholar
• Brown KA. Factors modifying the migration of lymphocytes across the blood-brain barrier. Int Immunopharmacol 2001; 1(12): 2043–62
  Article PubMed CAS Google Scholar
• Correale J, Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003; 140(1–2): 198–209
  Article PubMed CAS Google Scholar
• Zhang Y, Da R-R, Guo W, et al. Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis. J Clin Immunol 2005; 25(3): 254–64
  Article PubMed CAS Google Scholar
• Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128: 1747–63
  Article PubMed Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106–12
  Article PubMed CAS Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352(9139): 1498–504
  Article Google Scholar
• Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171(5): 2694–702
  PubMed CAS Google Scholar
• Huynh HK, Oger J, Dorovini-Zis K. Interferon-β downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60: 63–73
  Article PubMed CAS Google Scholar
• Miller A, Lanir N, Shapiro S, et al. Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells: implications for multiple sclerosis and other autoimmune diseases. J Neuroimmunol 1996; 64: 151–61
  Article PubMed CAS Google Scholar
• Soilu-Hänninen M, Salmi A, Salonen R. Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995; 60: 99–106
  Article PubMed Google Scholar
• Schreiner B, Mitsdoerffer M, Kieseier BC, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155: 172–82
  Article PubMed CAS Google Scholar
• Giorelli M, Livrea P, Defazio G, et al. IFN-beta la modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J Interferon Cytokine Res 2001; 21(10): 809–12
  Article PubMed CAS Google Scholar
• Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-la in multiple sclerosis. J Immunol 2001; 112: 153–62
  CAS Google Scholar
• Genc K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J Clin Invest 1997; 99: 2664–71
  Article PubMed CAS Google Scholar
• Kawanokuchi J, Mizuno T, Kato H, et al. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 2004; 46(5): 734–42
  Article PubMed CAS Google Scholar
• Shapiro S, Galboiz Y, Lahat N, et al. The ‘immunological-synapse’ at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β. J Neuroimmunol 2003; 144: 116–24
  Article PubMed CAS Google Scholar
• Sharief MK, Semra YK, Seidi OA, et al. Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001; 120: 199–207
  Article PubMed CAS Google Scholar
• Ahn J, Feng X, Patel N, et al. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-β therapy: implications for control of apoptosis. Frontiers in Bioscience 2004; 9: 1547–55
  Article PubMed CAS Google Scholar
• Billiau A, Kieseier BC, Hartung H-P. Biologic role of interferon beta in multiple sclerosis. J Neurol 2004; 251Suppl. 2: II/10–14
  CAS Google Scholar
• Zang YC, Skinner SM, Robinson RR, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler 2004; 10(5): 499–506
  Article PubMed Google Scholar
• Sega S, Wraber B, Mesec A, et al. IFN-beta la and IFN-beta 1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004; 106(3): 255–8
  Article PubMed Google Scholar
• Nagai T, Devergne O, Mueller TF, et al. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines. J Immunol 2003; 171(10): 5233–43
  PubMed CAS Google Scholar
• Maguire van Seventer J, Nagai T, VanSeventer GA. Interferon-β differentially regulates expression of the IL-12 family members p35, p40, pl9, and EB 13 in activated human dendritic cells. J Neuroimmunol 2002; 133: 60–71
  Article Google Scholar
• Hussien Y, Sanna A, Söderström M, et al. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001; 121: 102–10
  Article PubMed CAS Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924): 744–8
  Article PubMed CAS Google Scholar
• Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003; 24(4): 207–12
  Article PubMed CAS Google Scholar
• Vandenbroeck K, Alloza I, Gadina M, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 2004; 56(2): 145–60
  Article PubMed CAS Google Scholar
• Noronha A, Toscas A, Jensen MA. IFN-beta decreases T cell activation and IFN-gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145–54
  Article PubMed CAS Google Scholar
• Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interfer-on-β-1b. J Neuroimmunol 2000; 107(1): 100–7
  Article PubMed CAS Google Scholar
• Zang YCQ, Haider JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β. J Neuroimmunol 2001; 112(1-2): 174–80
  Article PubMed CAS Google Scholar
• Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 2004; 155(1–2): 161–71
  Article PubMed CAS Google Scholar
• Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348(1): 68–72
  Article Google Scholar
• Muraro PA, Leist T, Biekekova B, et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111(192): 186–94
  Article PubMed CAS Google Scholar
• Muraro PA, Liberati L, Bonanni L, et al. Decreased integrin gene expression in patients with MS responding to interferon-β treatment. J Neuroimmunol 2004; 150: 123–31
  Article PubMed CAS Google Scholar
• Jensen J, Krakauer M, Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta 1b. Cytokine 2005; 29(1): 24–30
  PubMed CAS Google Scholar
• Graber J, Zhan M, Ford D, et al. Inteferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005; 161: 169–76
  Article PubMed CAS Google Scholar
• Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402–8
  Article PubMed CAS Google Scholar
• Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997; 41: 669–74
  Article PubMed CAS Google Scholar
• Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111–6
  Article PubMed CAS Google Scholar
• Kraus J, Bauer R, Chatzimanolis N, et al. Interferon-β1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004; 251: 464–72
  Article PubMed CAS Google Scholar
• Calabresi PA, Prat A, Biernacki K, et al. T lymphocytes conditioned with interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol 2001; 115(1–2): 161–7
  Article PubMed CAS Google Scholar
• Matusevicius D, Kivisakk P, Navikas VV, et al. Influence of IFN-beta lb (Betafer-on) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 1998; 5(3): 265–75
  Article PubMed Google Scholar
• Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853–63
  Article PubMed CAS Google Scholar
• Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846–52
  Article PubMed CAS Google Scholar
• Ozenci V, Kouwenhoven M, Teleshova N, et al. Multiple sclerosis: pro-and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108(1–2): 236–43
  Article PubMed CAS Google Scholar
• Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001; 50: 443–51
  Article PubMed CAS Google Scholar
• Kraus J, Ling AK, Hamm S, et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56(2): 192–205
  Article PubMed CAS Google Scholar
• Hua LL, Kim MO, Brosnan CF, et al. Modulation of astrocyte inducible nitric oxide synthase and cytokine expression by interferon beta is associated with induction and inhibition of interferon gamma-activated sequence binding activity. J Neurochem 2002; 83(5): 1120–8
  Article PubMed CAS Google Scholar
• Lucas M, Sanchez-Solino O, Solano F, et al. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis. Neurochem Int 1998; 33: 101–2
  Article PubMed CAS Google Scholar
• Lucas M, Rodriguez MC, Gata JM, et al. Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem Int 2003; 42(1): 67–71
  Article PubMed CAS Google Scholar
• Hong J, Tejada-Simon MV, Rivera VM, et al. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler 2002; 8: 237–42
  Article PubMed CAS Google Scholar
• Alvarez-Lafuente R, De Las Heras V, Bartolome M, et al. Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission. Eur J Neurol 2004; 52(2): 87–91
  Article CAS Google Scholar
• Boutros T, Croze E, Yong VW. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997; 69: 939–46
  Article PubMed CAS Google Scholar
• Plioplys AV, Massimini N. Alpha/beta interferon is a neuronal growth factor. Neuroimmunomodulation 1995; 2(1): 31–5
  Article PubMed CAS Google Scholar
• Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702–8
  Article PubMed CAS Google Scholar
• Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 5556: 1704–14
  Article Google Scholar
• Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001; 2(7): 1149–65
  Article PubMed CAS Google Scholar
• Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92(1–2): 113–21
  Article PubMed CAS Google Scholar
• Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci 2000; 97(13): 7452–7
  Article PubMed CAS Google Scholar
• Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967–76
  Article PubMed CAS Google Scholar
• Allie R, Hu L, Mullen KM, et al. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol 2005; 62: 889–94
  Article PubMed Google Scholar
• Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon-β and copolymer-1. J Autoimmun 2005; 24: 119–24
  Article PubMed CAS Google Scholar
• Dabbert D, Rosner S, Kramer M, et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett 2000; 289(3): 205–8
  Article PubMed CAS Google Scholar
• Burns J, Littlefield K. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Neurology 1991; 41(8): 1317–9
  Article PubMed CAS Google Scholar
• Ziemssen T. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 2004; 541: 111–34
  Article PubMed CAS Google Scholar
• Ziemssen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125 (Pt 11): 2381–91
  Article PubMed Google Scholar
• Neuhaus O. Multiple sclerosis: immunological effects of mitoxantrone in vitro reveal antigen-presenting cells as major targets [abstract]. Eur J Neurol 2002; 9Suppl. 2: 130
  Google Scholar
• Fidler JM, DeJoy SQ, Gibbons JJ. Selective immunomodulation by the antineo-plastic agent mitoxantrone: I. Suppression of B lymphocyte function. J Immunol 1986; 137(2): 727–32
  PubMed CAS Google Scholar
• Gbadamosi J, Buhmann C, Tessmer W, et al. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003; 49: 137–41
  Article PubMed CAS Google Scholar
• Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforseen consequences. N Eng J Med. Epub 2005 Jun 9
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Eng J Med. Epub 2005 Jun 9
• Langer-Gould A, Atlas SW, Bollen AW, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med. Epub 2005 Jun 9
• Van Assche G, van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Eng J Med. Epub 2005 Jun 9
• Goldblum R, Messersmith E, Freedman S, et al. Mechanism of action (MOA) of natalizumab in inflammatory conditions [presentation nr 764; poster board nr 144]. American College of Rheumatology 68th Annual Scientific Meeting; 2004 Oct 16–21; Texas [online]. Available from URL: http://www.abstractsonline.com [Accessed 2005 Aug 19]
• Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466–72
  Article PubMed CAS Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110(6): 673–87
  Article PubMed CAS Google Scholar
• Qian F, Vaux DL, Weissman IL. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 1994, 77335
• Zhu Z, Sanchez-Sweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001; 61: 1707–16
  PubMed CAS Google Scholar
• Biogen Idec. Tysabri® (natalizumab) prescribing information 2004 [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/1251041bl.pdf [Accessed 2005 Aug 19]
• Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357–65
  PubMed CAS Google Scholar
• Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody campath 1H. Neurology 1999; 53: 751–7
  Article PubMed CAS Google Scholar
• Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225–37
  Article PubMed Google Scholar
• Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53(5): 680–4
  Article PubMed Google Scholar
• Bjartmar C, Trapp BD. Azonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003; 5(1-2): 157–64
  Article PubMed Google Scholar